PRTAProthena Corp. Plc

9.450USDMkt Cap: 485.13M $P/E:

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab…

Key Statistics

Company
Market Cap485.13M $
Enterprise Value182.37M $
Revenue (TTM)54.53M $
Gross Profit-10.42M $
Net Income (TTM)-244.09M $
Revenue/Share1.022 USD
Last Price9.450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINIE00B91XRN20
Valuation
P/E (Trailing)
P/E (Forward)-5.94
PEG
EV/EBITDA-3.09
EV/Revenue3.34
P/S8.50
P/B1.63
EPS (TTM)-0.80
EPS (Forward)-1.52
52W Range
9.09084% of range9.520
52W High9.520 USD
52W Low9.090 USD
Profitability
Gross Margin-19.11%
Oper. Margin-1850.20%
EBITDA Margin-108.27%
Profit Margin-2520.57%
ROE-87.03%
ROA-74.69%
Growth
Revenue Growth-77.10%
Earnings Growth
Cash Flow & Leverage
Operating CF-163.58M $
CapEx (TTM)138.00K $
FCF Margin-99.44%
FCF Yield-11.18%
Net Debt-281.20M $
Net Debt/EBITDA4.76
Balance Sheet
Debt/Equity0.03
Current Ratio25.05
Quick Ratio24.72
Book Value/Sh5.544 USD
Cash/Share5.614 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.40 USD
Upside (mean)+126.5%
Target Range8.000 USD36.00 USD
$8.000+126.5% to mean$36.00
# Analysts5
Ownership
Shares Out.51.34M
Float34.93M
Insiders22.11%
Institutions93.32%
Short Interest
Short Ratio15.0d
Short % Float19.17%
Short % Out.15.92%
Shares Short8.17M
Short (prev mo.)8.37M
Technical
SMA 508.893 (+6.3%)
SMA 2009.548 (-1.0%)
Beta-0.35
S&P 52W Chg21.00%
Avg Vol (30d)365.93K
Avg Vol (10d)402.01K
Technical Indicators
RSI (14)59.5
MACD0.0821
MACD Signal0.0053
MACD Hist.+0.0767
BB Upper9.521 USD
BB Middle8.795 USD
BB Lower8.069 USD
BB Width16.51%
ATR (14)0.4439 USD
Vol Ratio (20d)0.77x